Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

15.45USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$15.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
459,545
52-wk High
$27.50
52-wk Low
$9.73

Latest Key Developments (Source: Significant Developments)

Sangamo Announces UK Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease
Monday, 4 Jun 2018 08:00am EDT 

June 4 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES U.K. AUTHORIZATION OF CLINICAL TRIALS EVALUATING ZINC FINGER NUCLEASE IN VIVO GENOME EDITING TREATMENTS SB-318 FOR MPS I AND SB-913 FOR MPS II.SANGAMO THERAPEUTICS INC - EXPECTS TO INITIATE CLINICAL TRIAL SITES IN U.K. LATER THIS YEAR FOR SB-318 AND SB-913 PHASE 1/2 CLINICAL TRIALS.  Full Article

Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003
Wednesday, 16 May 2018 07:30am EDT 

May 16 (Reuters) - Sangamo Therapeutics Inc ::BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE.SANGAMO THERAPEUTICS - IND ENABLES BIOVERATIV TO INITIATE PHASE 1/2 CLINICAL TRIAL TO ASSESS SAFETY OF BIVV003 IN ADULTS WITH SICKLE CELL DISEASE.  Full Article

Sangamo Therapeutics Proposes Public Offering Of Common Stock
Tuesday, 24 Apr 2018 04:02pm EDT 

April 24 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SANGAMO THERAPEUTICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200.0 MILLION OF SHARES OF ITS COMMON STOCK.SANGAMO THERAPEUTICS - SEES USING NET PROCEEDS FROM OFFERING TO SUPPORT OWN, PARTNERED GENE THERAPY, GENOME EDITING, CELL THERAPY, AMONG OTHER THINGS.  Full Article

Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease
Wednesday, 28 Feb 2018 07:30am EST 

Feb 28 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES U.K. AUTHORIZATION OF CLINICAL TRIAL EVALUATING ZINC FINGER NUCLEASE IN VIVO GENOME EDITING TREATMENT FOR HEMOPHILIA B.SANGAMO THERAPEUTICS INC - EXPECTS TO INITIATE SITES IN U.K. LATER THIS YEAR FOR SB-FIX PHASE 1/2 CLINICAL TRIAL​.SANGAMO THERAPEUTICS INC - ‍EXPECTS TO FILE ADDITIONAL CTAS FOR SB-318 & SB-913 IN VIVO GENOME EDITING TREATMENTS FOR MPS I AND MPS II, RESPECTIVELY​.  Full Article

Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS - KITE TO RECEIVE EXCLUSIVE LICENSE TO LEVERAGE SANGAMO'S GENE EDITING TECHNOLOGY IN ALLOGENEIC AND AUTOLOGOUS CELL THERAPY PROGRAMS IN ONCOLOGY.SANGAMO THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION.SANGAMO THERAPEUTICS INC - UNDER TERMS, SANGAMO IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR AGREED UPON EXPENSES INCURRED BY SANGAMO.SANGAMO THERAPEUTICS INC - CO WOULD ALSO RECEIVE TIERED ROYALTIES ON SALES OF POTENTIAL FUTURE PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Sangamo Therapeutics Q4 Loss Per Share $0.15
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $13.1 MILLION VERSUS $8.9 MILLION.Q4 LOSS PER SHARE $0.15.Q4 EARNINGS PER SHARE VIEW $-0.18, REVENUE VIEW $11.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS INC - SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION AND IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PRODUCTS UNDER COLLABORATION.  Full Article

Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant
Wednesday, 7 Feb 2018 07:30am EST 

Feb 7 (Reuters) - Sangamo Therapeutics Inc ::CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV.NO SB-728-T PRODUCT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED IN SANGAMO'S SB-728-T CLINICAL TRIALS.CO WILL BE CONTRIBUTING MATERIALS, EQUIPMENT, AND MANUFACTURING EXPERTISE FOR STUDY, WHICH IS EXPECTED TO BEGIN IN 2018.  Full Article

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 07:31am EST 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Thursday, 7 Dec 2017 04:22pm EST 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE